Project HoloSurge
Multimodal 3D Holographic tool and real-time Guidance System with point-of-care diagnostics for surgical planning and interventions on liver and pancreatic cancers
Programme and Topic: HORIZON.2.1.5 - Tools, Technologies and Digital Solutions for Health and Care, including personalised medicine
Project duration: 2024 – 2027
UEG takes an active part in the project HoloSurge as a dissemination partner.
HoloSurge is a joint undertaking that brings European scientists and clinicians from high-tech companies, clinical centres, and research institutions in a consortium to deploy an innovative AI-based medical system that
- enables automatic fusion and segmentation of state-of-the-art imaging modalities for interactive 3D holographic visualization of patients’ organs;
- provides real-time surgical navigation, and
- allows real-time cell-level cancer diagnostics.
The solution will provide surgical teams with an unmatched holistic view of the patient’s anatomy and pathology in real-time at the point of care, before and during surgery. This innovation will be validated for cancer interventions while creating a trail of better-informed perioperative decision-making that can save countless lives.
This project has received funding from the European Union’s Horizon Europe research and innovation programme under grant agreement No Project 101137233 — HoloSurge. Horizon Europe is the EU’s key funding programme for research and innovation, with a budget of €95.5 billion.
Read press release Access official factsheet Visit HoloSurge website
Co-funded by the European Union. Views and opinions expressed are, however, those of the author(s) only and do not necessarily reflect those of the European Union or the European Health and Digital Executive Agency (HADEA). Neither the European Union nor the granting authority can be held responsible for them.
Project INTERCEPT – Pioneering a future without Crohn’s Disease
Full name: Verification and validation of a biomarker panel that identifies individuals at high risk to develop Crohn’s Disease allowing INTERCEPTION of full-blown disease development.
Programme and Topic: Clinical validation of biomarkers for diagnosis, monitoring disease progression and treatment response HORIZON-JU-IHI-2024-07-03
Project duration: 2025 – 2029
UEG supports this pioneering European study as an official dissemination partner.
The INTERCEPT project aims to verify and clinically validate a panel of biomarkers and build a blood risk score that can identify individuals with a high risk of developing Crohn’s Disease within five years after initial evaluation. The project will recruit 10,000 healthy first-degree relatives of individuals with Crohn’s Disease from seven European countries to further validate the biomarkers and risk score. From this group, 80 with the highest risk of developing Crohn’s Disease will take part in an innovative trial aimed at preventing full-blown disease development through an established and highly effective medical treatment. This early detection and prevention method has the potential to revolutionise the way we understand and treat Crohn’s Disease. It would enable healthcare professionals to diagnose the disease early on, potentially keeping it from progressing to debilitating stages. INTERCEPT is setting its sights on a future where Crohn’s Disease is highly manageable or even avoidable; committing itself to improving the lives of patients and their families.
The project INTERCEPT is supported by the Innovative Health Initiative Joint Undertaking (IHI JU) under grant agreement No 101194766. The JU receives support from the European Union’s Horizon Europe Research and Innovation Programme and COCIR, EFPIA, Europa Bío, MedTech Europe, Vaccines Europe, MoonLake Immunotherapeutics AG, ROPCA ApS, Scienta Lab, and Collective Minds Radiology AB.
Co-Funded by the European Union, the private members, and those contributing partners of the IHI JU. Views and opinions expressed are, however, those of the author(s) only and do not necessarily reflect those of the aforementioned parties. Neither of the aforementioned parties can be held responsible for them.
